Quick Answer
HeartSciences Inc. reported Total Revenue of $4.3 thousand for fiscal year 2025.
HeartSciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $4.3K -76.6% |
$18.6K +261.2% |
$5.2K -64.2% |
$14.4K | — |
| Revenue (ASC 606) | $4.3K -76.6% |
$18.6K +261.2% |
$5.2K -64.2% |
$14.4K | — |
| Net Income | -$8.77M -32.7% |
-$6.61M -3.9% |
-$6.35M -31.6% |
-$4.83M | — |
| Diluted EPS | -$9.34 +50.2% |
-$18.74 +76.6% |
-$80.00 -5417.2% |
-$1.45 | — |
| Total Assets | $4.22M -55.6% |
$9.50M +189.1% |
$3.29M +57.3% |
$2.09M | — |
| Cash and Equivalents | $1.10M -81.1% |
$5.81M +249.8% |
$1.66M +80.8% |
$918.3K | — |
| Stockholders Equity | $205.2K -97.2% |
$7.32M +3073.7% |
$230.6K +103.8% |
-$6.06M -217.1% |
-$1.91M |
| R&D Expense | $4.39M +52.4% |
$2.88M +17.0% |
$2.46M -18.0% |
$3.00M | — |
| Operating Income | -$8.35M -32.5% |
-$6.31M -3.2% |
-$6.11M -29.8% |
-$4.71M | — |
| Gross Profit | $2.5K -80.3% |
$12.5K +431.8% |
$2.4K -63.7% |
$6.5K | — |
| Shares Outstanding | 1.12M +65.4% |
676,598 +567.7% |
101,332 -97.0% |
3.32M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $0.00 | — | -100.0% |
| Revenue (ASC 606) | January 31, 2026 | $0.00 | — | -100.0% |
| Net Income | January 31, 2026 | -$1.99M | +21.7% | +15.6% |
| Diluted EPS | October 31, 2025 | -$0.85 | +62.6% | +46.2% |
| Total Assets | January 31, 2026 | $7.55M | +32.4% | +26.0% |
| Cash and Equivalents | January 31, 2026 | $3.40M | +30.8% | +74.1% |
| Stockholders Equity | January 31, 2026 | $2.65M | +48.4% | -36.6% |
| R&D Expense | January 31, 2026 | $638.6K | -38.2% | -12.2% |
| Operating Income | January 31, 2026 | -$1.93M | +18.7% | +7.0% |
| Gross Profit | January 31, 2026 | $0.00 | — | -100.0% |
| Shares Outstanding | January 31, 2026 | 3.18M | +208.5% | +3.7% |
- HeartSciences Inc. reported Total Revenue of $4.3 thousand for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -76.6% in Total Revenue compared to the prior fiscal year.
- HeartSciences Inc. reported Revenue (ASC 606) of $4.3 thousand for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -76.6% in Revenue (ASC 606) compared to the prior fiscal year.
- HeartSciences Inc. reported Net Income of -$8.77 million for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -32.7% in Net Income compared to the prior fiscal year.
- HeartSciences Inc. reported Diluted EPS of $9.34 per share (loss) for fiscal year 2025.
- HeartSciences Inc. showed an increase of +50.2% in Diluted EPS compared to the prior fiscal year.
- HeartSciences Inc. reported Total Assets of $4.22 million for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -55.6% in Total Assets compared to the prior fiscal year.
- HeartSciences Inc. reported Cash and Equivalents of $1.10 million for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -81.1% in Cash and Equivalents compared to the prior fiscal year.
- HeartSciences Inc. reported Stockholders Equity of $205.2 thousand for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -97.2% in Stockholders Equity compared to the prior fiscal year.
- HeartSciences Inc. reported R&D Expense of $4.39 million for fiscal year 2025.
- HeartSciences Inc. showed an increase of +52.4% in R&D Expense compared to the prior fiscal year.
- HeartSciences Inc. reported Operating Income of -$8.35 million for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -32.5% in Operating Income compared to the prior fiscal year.
- HeartSciences Inc. reported Gross Profit of $2.5 thousand for fiscal year 2025.
- HeartSciences Inc. showed a decrease of -80.3% in Gross Profit compared to the prior fiscal year.
- HeartSciences Inc. reported Shares Outstanding of 1.12 million shares for fiscal year 2025.
- HeartSciences Inc. showed an increase of +65.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: